SHP099

Target: SHP099 targets SHP2/PTPN11 at an allosteric pocket spanning SH2 and phosphatase domains.

Mechanism of Action: SHP099 is suitable as an allosteric SHP2-binding ligand for degrader engineering. In a PROTAC, the SHP099-derived portion recognizes the autoinhibited SHP2 conformation, while a linker connects it to an E3 ligase ligand. The degrader must support concurrent SHP2 and E3 engagement, because ternary-complex architecture determines whether ubiquitination can occur. When SHP2 is held near the ligase in a productive orientation, lysine ubiquitination is promoted, and the modified SHP2 protein is processed by the ubiquitin-proteasome system. This establishes a testable protein-depletion mechanism for research assays.

• SHP099 as E3 Recruitment Ligand: SHP099 can be used as a ligand component in PROTAC designs to engage SHP-family targets and drive proximity to an E3 ligase. This enables exploration of ubiquitin-mediated degradation pathways, allowing researchers to tune degradation potency, selectivity, and kinetics by varying linker length and E3 ligase recruitment motifs.

• Mapping Degradation Mechanisms: Incorporating SHP099 into PROTAC constructs supports mechanistic studies of targeted protein degradation. Researchers can assess whether degradation depends on specific E3 ligases, ubiquitination, and proteasome activity, using inhibitors and orthogonal readouts such as immunoblotting, live-cell degradation kinetics, and rescue experiments to confirm on-target, proximity-driven effects.

• Optimizing Linker and Potency: SHP099-based PROTACs are suitable for structure–activity relationship investigations. By systematically modifying linker composition, attachment points, and steric constraints, researchers can evaluate how these parameters influence ternary complex formation and downstream degradation efficiency, enabling rational optimization toward stronger target removal with minimized off-target degradation.

• Profiling SHP-Related Pathway Effects: PROTACs containing SHP099 can be applied to study functional consequences of degrading SHP-associated signaling nodes. Researchers can measure pathway modulation downstream of the degraded protein, compare degradation versus inhibition phenotypes, and identify biomarkers that correlate with extent of protein loss to clarify causal roles in cellular signaling networks.

SHP099 is an allosteric SHP2/PTPN11 inhibitor with a compact pyrazine-centered scaffold useful for phosphatase degrader exploration. Its basic aminopiperidine substituent and dichlorophenyl group offer a defined starting point for SAR-guided PROTAC linker attachment. This molecule is described in detail below.

Structure: The molecule is a substituted pyrazine bearing an amino group, a 2,3-dichlorophenyl ring, and a 4-amino-4-methylpiperidinyl substituent. The basic piperidine and heteroaryl amines provide polar contacts, while the dichloroaryl group adds hydrophobic recognition.

Reactivity: In SHP2 degrader design, the aminopiperidine substituent is a plausible region for linker-vector scanning because it is synthetically addressable, but modification must be guided by SHP2 allosteric-pocket SAR to avoid disrupting the closed-conformation binding mode. Alkyl, PEG, or amide-containing linkers may be paired with CRBN or VHL ligands, with alternative E3 recruiters considered if ternary-complex formation is weak.